The US FDA has extended its approval for AstraZeneca’s acalabrutinib to include initial treatment of mantle cell lymphoma (MCL) in adults who cannot undergo a hematopoietic stem cell transplant. MCL is a rare, aggressive blood cancer and acalabrutinib, sold as Calquence, is the first of its kind approved as front-line therapy for the disease. The drug already had accelerated approval for adults whose MCL had failed at least one prior treatment.
Sonatype reports rise in open source malware to 17,954
The 1Q 2025 Open Source Malware Index from Sonatype revealed that open source malware packages doubled compared to the same period last year, with 56%
